Teva Pharma (TEVA) / Mylan (MYL) Combo Unlikely, Says Wells Fargo

Wells Fargo analyst Michael Faerm commented on speculation Teva Pharma (NYSE: TEVA) is interested in acquiring Mylan (NASDAQ: MYL). In his view, a potential deal has positives and negatives, and while it may be financially attractive he thinks it is strategically unlikely.

Among other negatives, Faerm said a major generics acquisition is not likely Teva's first choice, and a deal would not significantly improve Teva's growth problem. He also said Mylan may not be a willing seller.

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $46.50 yesterday.

You May Also Be Interested In

• Paramount Global (PARA) and Skydance are closer to a merger - CNBC
• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Snow Lake Resources (LITM) Acquires Black Lake Uranium Project in the Athabasca Basin, Saskatchewan